{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T04:23:02Z","timestamp":1754194982512,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T00:00:00Z","timestamp":1579910400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T00:00:00Z","timestamp":1579910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s00296-020-04517-4","type":"journal-article","created":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T11:02:28Z","timestamp":1579950148000},"page":"1081-1087","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A treat-to-target approach for gout confers renoprotective effect in patients with chronic kidney disease stage 3"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2200-0859","authenticated-orcid":false,"given":"Marta","family":"Novella-Navarro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2880-509X","authenticated-orcid":false,"given":"Jose Luis","family":"Cabrera-Alarcon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6275-7699","authenticated-orcid":false,"given":"Cesar","family":"Diaz-Torne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Aramburu-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iustina","family":"Janta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Carmen","family":"Ortega de la O","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Prada-Ojeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5738-7133","authenticated-orcid":false,"given":"Luis","family":"Sala-Icardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8290-1846","authenticated-orcid":false,"given":"Ana","family":"Urruticoechea-Arana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6586-6903","authenticated-orcid":false,"given":"Paloma","family":"Garc\u00eda de la Pe\u00f1a Lefebvre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3095-0969","authenticated-orcid":false,"given":"Enrique","family":"Calvo-Aranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,25]]},"reference":[{"key":"4517_CR1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","volume":"11","author":"CF Kuo","year":"2015","unstructured":"Kuo CF, Grainge MJ, Zhang W, Doherty M (2015) Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol 11:649\u2013662","journal-title":"Nat Rev Rheumatol"},{"key":"4517_CR2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/1471-2369-15-122","volume":"15","author":"L Li","year":"2014","unstructured":"Li L, Yang C, Zhao Y, Zeng X, Liu F, Fu P (2014) Is hyperuricemia independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol 15:122","journal-title":"BMC Nephrol"},{"key":"4517_CR3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/HJH.0b013e3282f240bf","volume":"26","author":"DB Corry","year":"2008","unstructured":"Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML (2008) Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 26:269\u2013275","journal-title":"J Hypertens"},{"key":"4517_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11906-017-0793-3","volume":"19","author":"M Bove","year":"2017","unstructured":"Bove M, Cicero AFG, Borghi C (2017) The effect of xanthine oxidase inhibitors on blood pressure and renal function. Curr Hypertens Rep 19:95","journal-title":"Curr Hypertens Rep"},{"key":"4517_CR5","doi-asserted-by":"publisher","first-page":"e0161","DOI":"10.1097\/MD.0000000000010161","volume":"97","author":"XX Zeng","year":"2018","unstructured":"Zeng XX, Tang Y, Hu K, Zhou X, Wang J, Zhu L et al (2018) Efficacy of febuxostat in hyperuricemic patients with mild to moderate chronic kidney disease: a meta-analysis of randomized clinical trials: a PRISMA-compliant article. Medicine 97:e0161","journal-title":"Medicine"},{"key":"4517_CR6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1053\/j.ajkd.2014.11.016","volume":"65","author":"M Goicoechea","year":"2015","unstructured":"Goicoechea M, Garcia de Vinuesa S, Verdalles U, Verde E, Macias N, Santos A et al (2015) Allopurinol and progression of CKD and cardiovascular events: long term follow-up of a randomized clinical trial. Am J Kidney Dis 65:543\u2013549","journal-title":"Am J Kidney Dis"},{"key":"4517_CR7","doi-asserted-by":"publisher","first-page":"e0145506","DOI":"10.1371\/journal.pone.0145506","volume":"10","author":"S Uchida","year":"2015","unstructured":"Uchida S, Chang WX, Ota T, Tamura Y, Shiraishi T, Kumagai T et al (2015) Targeting uric acid and the inhibition of progression to end-stage renal disease\u2013a propensity score analysis. PLoS ONE ONE 10:e0145506","journal-title":"PLoS ONE ONE"},{"key":"4517_CR8","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1136\/annrheumdis-2016-209467","volume":"76","author":"U Kiltz","year":"2017","unstructured":"Kiltz U, Smolen J, Bardin T, Cohen Solal A, Dalbeth N, Doherty M et al (2017) Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis 76:632\u2013638","journal-title":"Ann Rheum Dis"},{"key":"4517_CR9","unstructured":"Reumatolog\u00eda GdtGSEd. Gu\u00eda de pr\u00e1ctica cl\u00ednica para el manejo de la gota (2013) https:\/\/www.ser.es\/practicaClinica\/GuipClinGot\/"},{"key":"4517_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Casta\u00f1eda-Sanabria J et al (2017) 2016 Updated EULAR evidence based-recommendations for the management of gout. Ann Rheum Dis 76:29\u201342","journal-title":"Ann Rheum Dis"},{"key":"4517_CR11","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","volume":"74","author":"T Neogi","year":"2015","unstructured":"Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D et al (2015) 2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 74:1789\u20131798","journal-title":"Ann Rheum Dis"},{"key":"4517_CR12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","volume":"158","author":"A Levin","year":"2013","unstructured":"Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco ALM, De Jong PE et al (2013) Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Ann Intern Med 158:825\u2013830","journal-title":"Ann Intern Med"},{"key":"4517_CR13","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1002\/art.39654","volume":"68","author":"KG Saag","year":"2016","unstructured":"Saag KG, Whelton A, Becker MA, MacDonald P, Hunt B, Gunawardhana L (2016) Impact of febuxostat on renal function in gout patients with moderate-to-severe renal impairment. Arthritis Rheumatol 68:2035\u20132043","journal-title":"Arthritis Rheumatol"},{"key":"4517_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","volume":"76","author":"KR Hande","year":"1984","unstructured":"Hande KR, Noone RM, Stone WJ (1984) Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 76:47\u201356","journal-title":"Am J Med"},{"key":"4517_CR15","first-page":"1646","volume":"33","author":"N Dalbeth","year":"2006","unstructured":"Dalbeth N, Kumar S, Stamp L, Gow P (2006) Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 33:1646\u20131650","journal-title":"J Rheumatol"},{"key":"4517_CR16","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1136\/annrheumdis-2014-205577","volume":"74","author":"WH Chung","year":"2015","unstructured":"Chung WH, Chang WC, Stocker SL, Juo CG, Graham GG, Lee MH et al (2015) Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis 74:2157\u20132164","journal-title":"Ann Rheum Dis"},{"key":"4517_CR17","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1136\/annrheumdis-2016-210872","volume":"76","author":"LK Stamp","year":"2017","unstructured":"Stamp LK, Chapman PT, Barclay ML, Horne A, Frampton C, Tan P et al (2017) A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis 76:1522\u20131528","journal-title":"Ann Rheum Dis"},{"key":"4517_CR18","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1136\/annrheumdis-2017-211210","volume":"76","author":"JA Singh","year":"2017","unstructured":"Singh JA, Cleveland JD (2017) Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: an analysis of Medicare claims data. Ann Rheum Dis 76:1669\u20131678","journal-title":"Ann Rheum Dis"},{"key":"4517_CR19","doi-asserted-by":"publisher","first-page":"274","DOI":"10.23876\/j.krcp.2017.36.3.274","volume":"36","author":"S Kim","year":"2017","unstructured":"Kim S, Kim HY, Ahn HS, Oh SW, Han KH, Um TH et al (2017) Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: a systematic review and meta-analysis. Kidney Res Clin Pract 36:274\u2013281","journal-title":"Kidney Res Clin Pract"},{"key":"4517_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.semarthrit.2012.03.013","volume":"42","author":"RV Curiel","year":"2012","unstructured":"Curiel RV, Guzman NJ (2012) Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review. Semin Arthritis Rheum 42:166\u2013178","journal-title":"Semin Arthritis Rheum"},{"key":"4517_CR21","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1053\/j.ajkd.2017.01.055","volume":"70","author":"AB Vargas-Santos","year":"2017","unstructured":"Vargas-Santos AB, Neogi T (2017) Management of gout and hyperuricemia in CKD. Am J Kidney Dis 70:422\u2013439","journal-title":"Am J Kidney Dis"},{"key":"4517_CR22","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/ndt\/gfw452","volume":"32","author":"J Xia","year":"2017","unstructured":"Xia J, Wang L, Ma Z, Zhong L, Wang Y, Gao Y et al (2017) Cigarette smoking and chronic kidney disease in the general population: a systematic review and meta-analysis of prospective cohort studies. Nephrol Dial Transplant 32:475\u2013487","journal-title":"Nephrol Dial Transplant"},{"key":"4517_CR23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s13075-018-1746-1","volume":"30","author":"M Roughley","year":"2018","unstructured":"Roughley M, Sultan AA, Clarson L, Muller S, Whittle R, Blecher J et al (2018) Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study. Arthritis Res Ther 30:243","journal-title":"Arthritis Res Ther"},{"key":"4517_CR24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1159\/000484279","volume":"192","author":"S Uchida","year":"2018","unstructured":"Uchida S, Kumagai T, Chang WX, Tamura Y, Shibata S (2018) Time to target uric acid to retard chronic kidney disease progression. Contrib Nephrol 192:56\u201368","journal-title":"Contrib Nephrol"},{"key":"4517_CR25","doi-asserted-by":"publisher","first-page":"i47","DOI":"10.1093\/rheumatology\/kex432","volume":"57","author":"P Richette","year":"2018","unstructured":"Richette P, Latourte A, Bardin T (2018) Cardiac and renal protective effects of urate-lowering therapy. Rheumatology (Oxford) 57:i47\u2013i50","journal-title":"Rheumatology (Oxford)"},{"key":"4517_CR26","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1007\/s10067-018-4065-7","volume":"37","author":"J Vazquez-Mellado","year":"2018","unstructured":"Vazquez-Mellado J, Pel\u00e1ez-Ballestas I, Burgos-Vargas R, \u00c1lvarez-Hernandez E, Garc\u00eda- M\u00e9ndez S, Pascual-Ramos V et al (2018) Improvement in OMERACT domains and renal function with regular treatment for gout: a 12-month follow-up cohort study. Clin Rheumatol 37:1885\u20131894","journal-title":"Clin Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-020-04517-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-020-04517-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-020-04517-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T00:40:00Z","timestamp":1611448800000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-020-04517-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,25]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["4517"],"URL":"https:\/\/doi.org\/10.1007\/s00296-020-04517-4","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"type":"print","value":"0172-8172"},{"type":"electronic","value":"1437-160X"}],"subject":[],"published":{"date-parts":[[2020,1,25]]},"assertion":[{"value":"24 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Novella-Navarro reports non-financial support from Sociedad Espa\u00f1ola de Reumatolog\u00eda during the conduct of the study; Dr. Cabrera-Alarcon has nothing to disclose; Dr. Diaz-Torne reports personal fees from Menarini and Gr\u00fcnenthal, outside the submitted work; Dr. Aramburu-Mu\u00f1oz has nothing to disclose; Dr. Calvo-Aranda reports non-financial support from Sociedad Espa\u00f1ola de Reumatolog\u00eda, during the conduct of the study; personal fees from Menarini, Gr\u00fcnenthal and SOBI, outside the submitted work; Dr. Garc\u00eda de la Pe\u00f1a Lefebvre has nothing to disclose; Dr. Janta reports personal fees from MENARINI and Gr\u00fcnenthal, outside the submitted work; Dr. Ortega de la O reports personal fees from Gr\u00fcnenthal, outside the submitted work; Dr. Prada-Ojeda reports personal fees from Menarini and Gr\u00fcnenthal, outside the submitted work; Dr. Sala-Icardo has nothing to disclose; Dr. Urruticoechea-Arana reports personal fees from GR\u00dcNENTHAL and MENARINI, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}